Data from 11 patients in an MD Anderson study of a cell therapy that uses natural killer (NK) cells from donors instead of patients' own T cells showed a high response rate and low toxicity. A multicenter, international Phase II study is planned.
The Supreme Court denied on Tuesday a motion to expedite its hearing of a case that could determine the future of the ACA. In December, an appeals court ruled the individual mandate was unconstitutional.
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Dallas-based Pieces Technologies builds software systems that integrate clinical data with information from local health clinics, food banks, and other community resources. The company raised a $25.7 series B round led by Concord Health Partners.
The device connects to a patient's smartphone, captures images and sends them to an orthodontist thereby taking the hassle of going to a dentist's office to straighten teeth among other things.
The Senate voted 72-18 Thursday to confirm Hahn, a radiation oncologist and chief medical executive at The University of Texas MD Anderson Cancer Center.
HHS announced that it had nominated Dr. Stephen Hahn as the next FDA commissioner. Acting Commissioner Ned Sharpless will return to the National Cancer Institute, while HHS official Brett Giroir will temporarily step in pending Hahn's confirmation.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Dr. Stephen Hahn, a radiation oncologist and MD Anderson's chief medical executive, has reportedly been in the running since September to succeed former FDA Commissioner Scott Gottlieb and current acting commissioner Ned Sharpless.
Shares of Texas-based Reata rose 60 percent Tuesday following the announcement of results from its registration-directed Phase II study of omaveloxolone. The company reacquired rights to that and other drugs from AbbVie last week. FA has no approved treatments.
BioCentury reported that the the nomination of radiation oncologist Dr. Stephen Hahn, who had been under consideration, would follow an FBI background check. Acting Commissioner Ned Sharpless and Brett Giroir, an assistant HHS secretary, had also reportedly been in the running.
Trump is reportedly considering Dr. Stephen Hahn to head the FDA. Others reportedly under consideration include acting Commissioner Ned Sharpless and HHS assistant secretary Brett Giroir.
This eBook, in collaboration with Care Logistics, details how hospitals and health systems can facilitate more effective decision-making by operationalizing elevated awareness.
The two organizations are placing particular emphasis on lung and gastrointestinal cancers, as well as drug targets like KRAS mutations.
The initiative, slated to be completed by the first half of 2021, is being undertaken after an unsuccessful effort to sell the division to a willing acquirer
Oscar, which was initially founded in 2012 to serve the emerging Obamacare insurance exchanges, decided to enter into Medicare Advantage after a $375 million funding round from Alphabet last year.
Vizient, a healthcare performance improvement company, will use its analytics and data capabilities to help Civica Rx anticipate gaps in drug availability and affordability.
Last month, the Austin, Texas-based VC announced the close of their third fund, a $250 million fund that exceeded the company's initial $200 million goal.